

<b>Subject:</b>	Jemperli (dostarlimab-gxly)		
<b>Document #:</b>	ING-CC-0197	<b>Publish Date:</b>	<del>10/04/2021</del> 09/19/2022
<b>Status:</b>	Revised	<b>Last Review Date:</b>	<del>09/13/2021</del> 08/19/2022

## Table of Contents

<a href="#">Overview</a>	<a href="#">Coding</a>	<a href="#">References</a>
<a href="#">Clinical criteria</a>	<a href="#">Document history</a>	

## Overview

This document addresses the use of Jemperli (dostarlimab-gxly). Jemperli is a human programmed death receptor-1 (PD-1) blocking antibody, indicated for the treatment of endometrial cancer.

The FDA approved indication for Jemperli is for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. Jemperli is also indication for recurrent or advanced dMMR solid tumors that have progressed on or following prior treatment, and who have no other satisfactory treatment options.

Jemperli (dostarlimab-gxly) was approved under the FDA's accelerated approval program, and continued approval is contingent upon verification of clinical benefit in confirmatory trials.

The National Comprehensive Cancer Network (NCCN) provides additional recommendation with a category 2A level of evidence for the use of Jemperli for various recurrent or advanced dMMR solid state tumors including, Ampullary adenocarcinoma, breast cancer, colon cancer, esophageal and esophagogastric junction cancers, gastric cancer, ovarian cancer, rectal cancer, and small bowel adenocarcinomas for those who have progressed on, or following, prior treatment and who have no other satisfactory treatment options.

### Definitions and Measures

**Chemotherapy:** Medical treatment of a disease, particularly cancer, with drugs or other chemicals.

**Disease-free survival (DFS):** The interval between a complete disappearance of the cancer (complete response) and the time of relapse.

**Disease Progression:** Cancer that continues to grow or spread.

**ECOG or Eastern Cooperative Oncology Group Performance Status:** A scale and criteria used by doctors and researchers to assess how an individual's disease is progressing, assess how the disease affects the daily living abilities of the individual, and determine appropriate treatment and prognosis. This scale may also be referred to as the WHO (World Health Organization) or Zubrod score which is based on the following scale:

- 0 = Fully active, able to carry on all pre-disease performance without restriction
- 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, for example, light house work, office work
- 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours
- 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
- 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
- 5 = Dead

**Immune checkpoint inhibitor:** A type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. When these proteins are blocked, the "brakes" on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include programmed death (PD)-1, PD-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen (CTLA)-4/B7-1/B7-2.

## Line of Therapy:

- First-line therapy: The first or primary treatment for the diagnosis, which may include surgery, chemotherapy, radiation therapy or a combination of these therapies.
- Second-line therapy: Treatment given when initial treatment (first-line therapy) is not effective or there is disease progression.
- Third-line therapy: Treatment given when both initial (first-line therapy) and subsequent treatment (second-line therapy) are not effective or there is disease progression.

Locally advanced cancer: Cancer that has spread only to nearby tissues or lymph nodes.

Maintenance therapy: Designed to maintain a condition to prevent a relapse.

Malignant: Cancerous. Malignant cells can invade and destroy nearby tissue and spread to other parts of the body.

Metastasis: The spread of cancer from one part of the body to another; a metastatic tumor contains cells that are like those in the original (primary) tumor and have spread.

Programmed death (PD)-1 proteins: PD-1 proteins are found on T-cells and attach to PD ligands (PD-L1) found on normal (and cancer) cells (see immune checkpoint inhibitor above). Normally, this process keeps T-cells from attacking other cells in the body. However, this can also prevent T-cells from attacking cancer cells in the body. Examples of FDA approved anti-PD-1 agents include Keytruda (pembrolizumab), Opdivo (nivolumab), and Libtayo (cemiplimab).

Programmed death ligand (PD-L)-1: The ligands found on normal (and cancer) cells to which the PD-1 proteins attach (see immune checkpoint inhibitor above). Cancer cells can have large amounts of PD-L1 on their surface, which helps them to avoid immune attacks. Examples of FDA approved anti-PD-L1 agents include Bavencio (avelumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab).

Progressive Disease (PD): Cancer that is growing, spreading, or getting worse.

## Clinical Criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

### Jemperli (dostarlimab-gxly)

Requests for Jemperli (dostarlimab-gxly) may be approved if the following criteria are met:

- I. Individual has a diagnosis of Endometrial Cancer (EC); **AND**
  - A. Individual has recurrent or advanced, mismatch repair deficient (dMMR) disease with test results confirmed; **AND**
  - B. Individual is using as monotherapy following confirmed disease progression with a platinum-containing regimen; **AND**
  - C. Individual has not received treatment with another anti-PD-1 or anti-PD-L1 agent; **AND**
  - D. Individual has a current ECOG performance status of 0-2; **AND**
  - E. Individual is not receiving therapy for an autoimmune disease or chronic condition requiring treatment with a systemic immunosuppressant;
- OR**
- II. Individual has a diagnosis of Solid Tumors; **AND**
  - A. Individual has recurrent or advanced, mismatch repair deficient (dMMR) disease with test results confirmed; **AND**
  - B. Individual has confirmed disease progression following prior treatment with no other satisfactory alternative treatment options; **AND**
  - C. Individual has not received treatment with another anti-PD-1 or anti-PD-L1 agent; **AND**
  - D. Individual has a current ECOG performance status of 0-2; **AND**
  - E. Individual is not receiving therapy for an autoimmune disease or chronic condition requiring treatment with a systemic immunosuppressant.

Jemperli (dostarlimab) may not be approved when the above criteria are not met and for all other indications.

## Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement.

policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

### HCPCS

<b>J9272</b>	Injection, dostarlimab-gxly, 10 mg, [Jemperli]
--------------	--

### ICD-10 Diagnosis

<b>C00.0-C76.8</b>	Malignant neoplasm at various anatomical sites
<b>C54.0-C54.9</b>	Malignant neoplasm of corpus uteri
<b>Z15.09</b>	Genetic susceptibility to other malignant neoplasm

## Document History

Reviewed: 08/19/2022

### Document History:

- 08/19/2022 – Annual Review: Update references. No criteria changes. Updates from NCCN guidelines reiterate FDA approved usage in dMMR solid state tumors. Coding reviewed: No changes.
- 09/13/2021 – Selected Review: Update criteria to add new indication for dMMR solid tumors per label. Wording and formatting changes. Coding reviewed: Added HCPCS C9082. Added ICD-10-CM, C00.0-C76.08, C54.0-C54.9, Z15.09. Coding Reviewed: 1/1/2022 Added HCPCS J9272. Removed C9082, J3490, J3590, J9999. Removed all diagnoses pend.
- 05/21/2021 – Annual Review: Add new clinical criteria document for Jemperli. Coding Reviewed: Added J3490, J3590, J9999. All diagnosis pend.

## References

1. Clinical Pharmacology powered by ClinicalKey. Tampa (FL): Elsevier. 2022. Available from: <http://www.clinicalkey.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 24, 2022.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2022 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on June 24, 2022
  - a. Ampullary Adenocarcinoma. V1.2022. Revised March 9, 2022
  - b. Breast Cancer. V4.2022. Revised June 21, 2022.
  - c. Colon Cancer. V1.2022. Revised February 25, 2022.
  - d. Esophageal and Esophagogastric Junction Cancers. V2.2022. Revised February 11, 2022.
  - e. Gastric Cancer. V2.2022. Revised January 11, 2022.
  - f. Occult Primary. V1.2022. Revised September 2, 2021.
  - g. Ovarian Cancer. V1.2022. Revised January 18, 2022.
  - h. Rectal Cancer. V1.2022. Revised February 25, 2022.
  - i. Small Bowel Adenocarcinoma. V1.2022. Revised March 9, 2022.
  - j. Uterine Neoplasms. V1.2022. Revised November 4, 2022.
6. Oaknin A, Tinker AV, Gilbert L, et al. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial [published online ahead of print, 2020 Oct 1]. *JAMA Oncol*. 2020;6(11):1-7. doi:10.1001/jamaoncol.2020.4515. Available at: <https://jamanetwork.com/journals/jamaoncology/fullarticle/2771011>.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association